BIOVIE INC. cotiza a 1.32 USD y tiene una capitalización bursátil de $11M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due …
| Periodo | 2026-11 | 2026-08 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | — | $-0.98 | $-11.05 |
| Estimado | — | $-0.52 | $-0.79 | $-3.60 |
| Sorpresa | — | — | -24.1% | -206.9% |
| Métrica | BIVI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -214.9% | -40.4% | -174.5% |
| ROA | -154.9% | -32.0% | -122.9% |
| Current Ratio | 3.59 | 2.84 | +0.75 |
| Debt / Equity | — | 0.28 | — |